Response Genetics

Response Genetics EBIT Margin

The EBIT Margin (Operating Margin) of Response Genetics (RGDXQ) as of Oct 24, 2026 is -118.50 %. In the previous year, EBIT Margin (Operating Margin) was -77.80 % — a change of 52.32% (lower).

EBIT Margin

-118.50 %

YoY

52.32%

Last updated:

EBIT Margin (Operating Margin) of Response Genetics is 2015 -118.50 % . EBIT Margin (Operating Margin) of Response Genetics was 2014 -77.80 % . It decreases by 52.32% lower compared to the previous year.

For Response Genetics, the operating (EBIT) margin of -118.5% is down versus -25.1% a few years ago.

The Response Genetics EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2008
-1.38 USD
Jan 1, 2009
-1.04 USD
Jan 1, 2010
-0.23 USD
Jan 1, 2011
-0.25 USD
Jan 1, 2012
-0.41 USD
Jan 1, 2013
-0.40 USD
Jan 1, 2014
-77.80 USD
Jan 1, 2015
-118.50 USD
The Response Genetics EBIT Margin history
YEAREBIT MarginYoY
-118.50 %+52.32%
-77.80 %+19,286.93%
-0.40 %-1.81%
-0.41 %+62.86%
-0.25 %+9.39%
-0.23 %-77.89%
-1.04 %-25.03%
-1.38 %+96.09%
-0.71 %+159.79%
-0.27 %-198.27%
0.28 %-298.70%
-0.14 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Response Genetics Stock analysis

What does Response Genetics do? Response Genetics, Inc. generates revenue through the research, development, and sale of pharmacogenomic diagnostic tests for cancer treatment. The company offers ResponseDX diagnostic testing products, which utilize polymerase chain reaction, microarray methods, and fluorescence in situ hybridization (FISH) to analyze single biomarkers or gene profiles from patient tissue samples. Pharmaceutical companies in the United States, Asia, and Europe purchase the firm's pharmacogenomic clinical trial testing services, which provide genetic information from patient specimens to support drug development. The company's primary market segments include oncology-focused healthcare providers and pharmaceutical firms seeking to integrate genetic data into cancer therapy protocols. Response Genetics' revenue streams are derived from both direct sales of diagnostic products and contract-based clinical trial services. The firm's pharmacogenomic tests are designed to guide cancer treatment decisions by analyzing genetic markers, while its clinical trial services cater to pharmaceutical companies developing new oncology drugs. The company's product portfolio centers on ResponseDX, which is marketed to healthcare institutions and integrated into clinical workflows for personalized cancer care. The business model relies on the sale of diagnostic testing services and clinical trial support to pharmaceutical clients across multiple regions. Response Genetics' testing platforms enable the extraction and analysis of nucleic acids from patient samples, delivering actionable pharmacogenomic data. This data is used by pharmaceutical companies to tailor drug development and by healthcare providers to personalize treatment plans for cancer patients. Response Genetics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Response Genetics stock

EBIT Margin (Operating Margin) of Response Genetics is -118.50 % in 2015.

EBIT Margin (Operating Margin) of Response Genetics changed from -77.80 % to -118.50 %, representing a 52.32% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Response Genetics since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Response Genetics with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Response Genetics

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Response Genetics